Cipla in the news
Global pharmaceutical leader
Tamtam found 20 recent articles about Cipla.
- Cipla - IndiGo, Tata Motors PV among 10 Nifty stocks facing earnings downgrades
Cipla and Power Grid Corporation have both experienced earnings downgrades for fiscal years 2027 and 2028.
- Stocks for quick gains: Know target price, stop loss for GAIL, Tata Consumer and Cipla
A technical analyst recommends buying stocks of GAIL, Tata Consumer Products, and Cipla, providing specific target prices and stop-loss levels for potential gains.
- Market wrap: SBI, Cipla, Titan Company, HDFC Life top gainers and losers on Nifty and Sensex on Wednesday
Indian equity benchmarks Nifty 50 and BSE Sensex closed lower on Wednesday due to profit booking, though the Pharma index gained.
- Tugain by Cipla highlights study showing 10,000+ new hairs in 3 months | *Based on an internal ingredient-based study | Inshorts
Cipla's Tugain Hair Growth Serum study demonstrated over 10,000 new hairs in 3 months for both male and female users.
- Sensex Dips 0.61% Amid Broad Market Weakness; Cipla and Urban Company Shine
Indian equities experienced a broad-based decline, with Sensex down 0.61%, although Cipla notably rose, while most sectors fell due to cautious global sentiment.
- Cipla, Tata Consumer, SBI Share Price Remains Firm, HDFC Life, Titan Bajaj Finance Decline; NSE Nifty Trades One Percent Lower
Indian stock markets experienced a decline with Nifty trading lower, although Cipla and other specific stocks saw gains, while gold-related shares fell due to declining gold prices.
- Stocks in Focus: Ashoka Buildcon, Cipla, RITES, and Others
Several Indian companies, including Cipla, Ashoka Buildcon, RITES, Biocon, and NDR Auto Components, have announced significant business developments, ranging from regulatory approvals and project wins to new collaborations and joint ventures.
- Cipla reports 'No Action Indicated' classification from USFDA for InvaGen facility inspection
Cipla's US-based InvaGen facility received a 'No Action Indicated' classification from the USFDA after a recent inspection, confirming its adherence to manufacturing standards.
- DRI Searches Cipla Office in Mumbai and Bhiwandi Depot Over Imported Drug Duty Claims
DRI searched Cipla's offices and depot regarding customs duty claims on an imported drug.
- Top stocks to watch today: Senco Gold, Adani Enterprises, BSE, Cipla shares in focus on Tuesday, 17 November | Full list
Several companies, including Senco Gold, Adani Enterprises, BSE, Cipla, and HDFC Life, are in focus due to business updates, regulatory approvals, and fundraising plans.
- Cipla DRI Search at Mumbai Office, Bhiwandi Depot
Cipla's Mumbai office and Bhiwandi depot were searched by the DRI regarding an imported pharmaceutical product's classification, with the company cooperating and reporting no material impact.
- Cipla stock faces DRI search at Mumbai office and depot
Cipla faced a DRI search at its Mumbai office and Thane depot concerning an imported pharmaceutical product, coinciding with a reported decline in its Q2 revenue and net income.
- Cipla's InvaGen New York facility gets USFDA's No Action Indicated classification
Cipla's US subsidiary InvaGen received a No Action Indicated classification from the USFDA for its New York facility, while Cipla's Mumbai and Thane locations were searched by the Directorate of Revenue Intelligence.
- Stocks to Watch Today: Urban Company, Senco Gold, ARSS Infra, Capri Global Capital, SML Mahindra, Lemon...
This article lists various stocks to watch on November 17, including Cipla.
- डीआरआई ने आयातित दवा के मामले में सिप्ला के मुंबई कार्यालय, भिवंडी स्थित गोदाम की तलाशी ली
Cipla's Mumbai office and Bhiwandi warehouse were searched by DRI in connection with the classification of an imported drug.
- Why Indian drugmakers are losing pricing power in the US
Indian drugmakers are losing pricing power in the US market due to increased competition and buyer concentration, leading to declining sales and a strategic shift towards complex products.
- DRI searches Cipla’s Mumbai office and Bhiwandi depot over imported drug classification
DRI conducted searches at Cipla's office and depot regarding the classification of an imported pharmaceutical product.
- DRI searches Cipla's Mumbai office, Bhiwandi depot over imported drugs
DRI searched Cipla's office and depot regarding an imported pharmaceutical product's classification.
- Stocks To Watch: 17 नवंबर को Urban Company, SML Mahindra, Cipla समेत इन शेयरों में दिख सकती है तेज हलचल
Several stocks, including Cipla, are expected to experience significant market activity on November 17th due to various business-related developments.
- DRI search at Cipla involving imported pharma product
Cipla was subject to a DRI search regarding an imported pharmaceutical product, with no material impact on the company.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Cipla?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies